MedTrace Logo

Study of CHO-A04 in Advanced Solid Tumors

NCT07049458 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2025-07-03

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if the study drug, CHO-A04, works to treat solid cancers in adults. It will also aim to learn about the safety of CHO-A04 and find the best dose to use in future cancer treatment. The main questions it aims to answer are:

* Which dose of CHO-A04 shows the best anti-cancer ability?
* How will your body respond to CHO-A04 treatment?
* How long will CHO-A04 remain in your body?

There are two stages of investigation in this study:

* Phase I: to find the best anti-cancer dose of CHO-A04
* Phase IIa: to find the CHO-A04 anti-cancer ability in specific cancer types

In this study, each participant will be assigned to one of the CHO-A04 dose levels. Participants will have CHO-A04 infusion via blood vessel once every week for four weeks. The CHO-A04 treatment may continue based on participants' condition and CHO-A04 safety evaluations.

Conditions

Interventions

DRUG

CHO-A04

CHO-A04 will be given intravenously (IV) once weekly for 4 weeks as a treatment cycle.

Sponsors & Collaborators

  • Cho Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • Chia-Chi (Josh) Lin, M.D., PhD. · National Taiwan University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2027-10-01
Completion
2028-10-01
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07049458 on ClinicalTrials.gov